What is it about?
Serotonergic antidepressants are associated with elevated risk of hospitalization and mortality. This underscores the importance of having a collaborative care and patient centered approach to manage depression in patients with chronic obstructive pulmonary disease (COPD) is worthy of consideration. Prospective randomized controlled trials are needed to determine the efficacy of serotonergic antidepressants therapy in long-term follow-up whether it is causal or merely a marker of for elevated mortality risk in patients with COPD, before denying our patients with major depression this valuable and efficacious therapy.
Read the Original
This page is a summary of: Serotonergic antidepressants in COPD: beneficial or harmful?, European Respiratory Journal, July 2018, European Respiratory Society (ERS), DOI: 10.1183/13993003.01095-2018.
You can read the full text:
The following have contributed to this page